Managing Clopidogrel Hypersensitivity without Interrupting Therapy: The Toronto Approach

Curr Vasc Pharmacol. 2019;17(2):119-122. doi: 10.2174/1389200219666180820114435.

Abstract

Clopidogrel remains a widely used antiplatelet agent for patients with established or high risk of atherothrombotic disease, particularly those treated with coronary, carotid or peripheral endovascular stenting. Clopidogrel hypersensitivity is an uncommon but well established adverse drug reaction presenting a challenge for patient management. The clinical presentation ranges from focal or diffuse cutaneous manifestations in most patients to angioedema in some and a systemic immune response in rare cases. The treatment options include drug discontinuation with or without desensitization therapy, switching to alternate ADP receptor antagonists or administration of oral steroids while continuing clopidogrel in patients at high risk of adverse events with clopidogrel discontinuation. In this review the author describes the phenomenon of clopidogrel hypersensitivity, various treatment strategies.

Keywords: ADP receptor antagonist; Clopidogrel; adverse drug reaction; drug allergy; hypersensitivity; skin rash..

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use*
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / drug therapy*
  • Clinical Protocols
  • Clopidogrel / administration & dosage*
  • Clopidogrel / adverse effects
  • Desensitization, Immunologic*
  • Drug Administration Schedule
  • Drug Hypersensitivity / diagnosis
  • Drug Hypersensitivity / immunology
  • Drug Hypersensitivity / therapy*
  • Drug Substitution*
  • Humans
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Purinergic P2Y Receptor Antagonists / administration & dosage*
  • Purinergic P2Y Receptor Antagonists / adverse effects
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Clopidogrel